Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We’ll look at the fund’s top holdings, buys, and sells.
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.
Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.
The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.
